The lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum

Journal of Immunotherapy

Volumn 32, Issue 3, 2009, Pages 292-301

  Westwood, Jennifer A ^a   Murray, William K ^a   Trivett, Melanie ^a   Haynes, Nicole M ^a   Solomon, Benjamin ^a   Mileshkin, Linda ^a   Ball, David ^a   Michael, Michael ^a   Burman, Angela ^a   Mayura Guru, Preethi ^a   Trapani, Joseph A ^a   Peinert, Stefan ^a   Hönemann, Dirk ^a   Miles Prince, H ^a   Scott, Andrew M ^a   Smyth, Mark J ^a   Darcy, Phillip K ^a   Kershaw, Michael H ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Adoptive immunotherapy; Gene therapy; Retroviral vector; Tumor associated antigen

Indexed keywords

CARBOHYDRATE ANTIGEN; CD28 ANTIGEN; GAMMA INTERFERON; LEWIS Y ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; DNA MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE; TUMOR CELL; BIOSYNTHESIS; BLOOD; BLOOD GROUP LEWIS SYSTEM; CYTOTOXICITY; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; NEOPLASM; PATHOLOGY; TRANSPLANTATION; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LEWIS BLOOD-GROUP SYSTEM; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 67449100831     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31819b7c8e     Document Type: Article

References (47)

1. Sebestyen Z, Schooten E, Sals T, et al. Human TCR that incorporate CD3{zeta}induce highly preferred pairing between TCR{alpha}and{beta}chains following gene transfer. J Immunol. 2008; 180:7736.
2. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126.
3. Coccoris M, Swart E, de Witte MA, et al. Long-term functionality of TCR-transduced T cells in vivo. J Immunol. 2008; 180:6536.
4. Ho WY, Blattman JN, Dossett ML, et al. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell. 2003;3:431.
5. Kershaw MH, Teng MW, Smyth MJ, et al. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol. 2005;5:928.
6. Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther. 2004;10:5.
7. Ahmed N, Ratnayake M, Savoldo B, et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007;67:5957.
8. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12 (20 Pt 1):6106.
9. Murphy A, Westwood JA, Brown LE, et al. Antitumor activity of dual-specific T cells and influenza virus. Cancer Gene Ther. 2007;14:499.
10. Lamers CH, Langeveld SC, Groot-van Ruijven CM, et al. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother. 2007;56:1875.
11. Ma Q, Safar M, Holmes E, et al. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate. 2004;61:12.
12. Pinthus JH, Waks T, Malina V, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest. 2004;114:1774.
13. Mansoor W, Gilham DE, Thistlethwaite FC, et al. Engineering T cells for cancer therapy. Br J Cancer. 2005;93:1085.
14. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9:279.
15. Cheadle EJ, Gilham DE, Thistlethwaite FC, et al. Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. Br J Haematol. 2005;129:322.
16. Rossig C, Bollard CM, Nuchtern JG, et al. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer. 2001;94:228.
17. Yun CO, Nolan KF, Beecham EJ, et al. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia. 2000;2:449.
18. Mezzanzanica D, Canevari S, Mazzoni A, et al. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. Cancer Gene Ther. 1998;5:401.
19. Hombach A, Sircar R, Heuser C, et al. Chimeric anti-TAG72 receptors with immunoglobulin constant Fc domains and gamma or zeta signalling chains. Int J Mol Med. 1998;2:99.
20. McGuinness RP, Ge Y, Patel SD, et al. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther. 1999;10:165.
21. Power BE, Caine JM, Burns JE, et al. Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector. Cancer Immunol Immunother. 2001;50:241.
22. Scott AM, Geleick D, Rubira M, et al. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res. 2000;60:3254.
23. Westwood JA, Smyth MJ, Teng MW, et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA. 2005;102:19051.
24. Yin BW, Finstad CL, Kitamura K, et al. Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer. Int J Cancer. 1996;65:406.
25. Miyake M, Taki T, Hitomi S, et al. Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. N Engl J Med. 1992;327:14.
26. Sakamoto J, Furukawa K, Cordon-Cardo C, et al. Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. Cancer Res. 1986;46:1553.
27. Zhang S, Zhang HS, Cordon-Cardo C, et al. Selection of tumor antigens as targets for immune attack using immuno-histochemistry: II. Blood group-related antigens. Int J Cancer. 1997;73:50.
28. Ichihara T, Sakamoto J, Nakao A, et al. Expression of blood group-related antigens in normal and malignant pancreatic tissue correlated with genotype of the patient defined by saliva glycoprotein. Cancer. 1993;71:71.
29. Kobayashi K, Sakamoto J, Kito T, et al. Lewis blood group-related antigen expression in normal gastric epithelium, intestinal metaplasia, gastric adenoma, and gastric carcinoma. Am J Gastroenterol. 1993;88:919.
30. Minato H, Nakanuma Y, Terada T. Expression of blood group-related antigens in cholangiocarcinoma in relation to non-neoplastic bile ducts. Histopathology. 1996;28:411.
31. Pastan I, Lovelace ET, Gallo MG, et al. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res. 1991;51:3781.
32. Kitamura K, Stockert E, Garin-Chesa P, et al. Specificity analysis of blood group Lewis-y [Le(y)] antibodies generate-dagainst synthetic and natural Le(y) determinants. Proc Natl Acad Sci USA. 1994;91:12957.
33. Schroder FH, Carter HB, Wolters T, et al. Early detection of prostate cancer in 2007 part 1: PSA and PSA kinetics. Eur Urol. 2008;53:468.
34. Alvarez RD, To A, Boots LR, et al. CA125 as a serum marker for poor prognosis in ovarian malignancies. Gynecol Oncol. 1987;26:284.
35. Guadagni F, Ferroni P, Carlini S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res. 2001;7:2357.
36. Lipton A, Leitzel K, Ali SM, et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer. 2005;104:257.
37. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem. 1990;265:15286.
38. Paxton RJ, Mooser G, Pande H, et al. Sequence analysis of carcinoembryonic antigen: identification of glycosylation sites and homology with the immunoglobulin supergene family. Proc Natl Acad Sci USA. 1987;84:920.
39. Gilham DE, O'Neil A, Hughes C, et al. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J Immunother. 2002;25:139.
40. Nolan KF, Yun CO, Akamatsu Y, et al. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res. 1999;5:3928.
41. Hombach A, Koch D, Sircar R, et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther. 1999;6:300.
42. Scott AM, Tebbutt N, Lee FT, et al. A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin Cancer Res. 2007;13:3286.
43. Krug LM, Milton DT, Jungbluth AA, et al. Targeting Lewis Y [Le(y)] in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels. J Thorac Oncol. 2007;2:947.
44. Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors. J Clin Oncol. 2000;18:2282.
45. Tolcher AW, Sugarman S, Gelmon KA, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 1999;17:478.
46. Oruzio DV, Aulmann C, Eller N. Results from a Phase I clinical trial with IGN311, a fully humanized IgG1 antibody against Lewis Y in patients with solid tumors. Proc Am Soc Clin Oncol. 2004:abstract number 2624.
47. Tahtis K, Lee FT, Smyth FE, et al. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab′)(2) constructs in a breast carcinoma xenograft model. Clin Cancer Res. 2001;7:1061.